Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO4929097 with Bevacizumab in Recurrent Malignant Glioma
NCT01189240Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RO4929097 in malignant glioma (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum-tolerated Dose at 28 days, Recommended Phase II Dose at 28 days and 1 more. Started Dec 2010; status: terminated.
02
Drugs
RO4929097
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT01189240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189240.